COLORADO SPRINGS, Colo., Oct. 9 /PRNewswire-FirstCall/ -- Spectranetics
Corporation (Nasdaq: SPNC) today announced it has received reimbursement
approval from the competent governmental authority in Belgium for its lead
removal and peripheral atherectomy product line, effective October 1, 2007.

The reimbursement for the lead removal indication -- an embedded,
infected lead or an electronic malfunction of a pacemaker or defibrillator
electrode -- applies to hospitals in Belgium that meet the national cardiac
pathology requirements and standards. The reimbursement for the peripheral
indication applies to all centers in Belgium equipped with Spectranetics'
technology for patients that suffer from critical limb ischemia with
non-healing ulcers or rest pain due to infrapopliteal disease.

Shar Matin, Managing Director of Spectranetics International, B.V.
commented, "We are very pleased that the Belgian authority granted
reimbursement approval for our laser-based therapies. Belgian patients now
have greater access to our life-changing technology. Reimbursement
initiatives are a cornerstone of Spectranetics International's strategy and
this approval follows the reimbursement approval in Germany for our
peripheral atherectomy device earlier this year."

About Spectranetics

Founded in 1984, Spectranetics manufactures and sells the only excimer
laser approved in the United States, Europe and Japan for use in minimally
invasive cardiovascular procedures. This technology treats complex
cardiovascular conditions by photo-ablating multiple lesion types into tiny
particles that are easily absorbed into the blood stream. The Company's
disposable catheters use high-energy "cool" ultraviolet light to vaporize
arterial blockages in the legs and heart, as well as scar tissue
encapsulating pacing and defibrillation leads. For more information visit
http://www.spectranetics.com.

Safe Harbor Statement

This news release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934. Such statements are based on current
assumptions that involve risks and uncertainties that could cause actual
outcomes and results to differ materially. These risks and uncertainties
may include increasing price and product competition, increased pressure on
expense levels resulting from expanded marketing and clinical activities,
uncertain success of the Company's strategic direction, dependence on new
product development, intellectual property claims of third parties,
availability of inventory from suppliers, the receipt of FDA approval to
market new products or applications and the timeliness of any approvals,
the potential size of market opportunities associated with new products,
market acceptance of new products or applications, product defects,
unexpected delays or costs associated with the Company's relocation and
consolidation of its headquarters and manufacturing operations, price
volatility due to the initiation or cessation of coverage, or changes in
ratings, by securities analysts. For a further list and description of such
risks and uncertainties that could cause the actual results, performance or
achievements of the Company to be materially different from any anticipated
results, performance or achievements, please see the Company's previously
filed SEC reports. Spectranetics disclaims any intention or obligation to
update or revise any financial projections or forward-looking statements,
whether as a result of new information, future events or otherwise.

(Date:8/16/2017)... ... August 16, 2017 , ... The Data Council, ... that it was acquired by Advantage Solutions. The Data Council’s IX-ONE platform ... include the industry’s leading suppliers, brokers, distributors and retailers. The Data Council will ...

(Date:7/26/2017)... Medical Aesthetics, a leading medical aesthetic clinic in Singapore ... several skin conditions from the inside. The natural process ... The skin becomes more transparent due to the thinning of the ... from the sun contributes to aging skin, causing age spots and ... ...